Scarica l'app Stockscreener
4.11
3.97%
-0.17
Dopo l'orario di chiusura:
4.11
4 D Molecular Therapeutics Inc Borsa (FDMT) Ultime notizie
Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com
Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World
4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com
4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks
4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq
4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire
4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan
Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World
FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World
Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World
2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.
Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex
4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance
Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com
4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World
Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World
4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks
Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga
RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk - Marketscreener.com
4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance UK
4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position - TipRanks
FDMT stock touches 52-week low at $4.4 amid sharp annual decline - Investing.com Australia
4D Molecular Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
4D Molecular Therapeutics, Inc. SEC 10-K Report - TradingView
4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times
4D Molecular Therapeutics Reports Positive Clinical Data for 4D-150 in Wet AMD and DME, Outlines Strategic Pipeline and Financial Position - Nasdaq
Can 4DMT's $505M Cash Runway and Promising Eye Disease Data Overcome Rising Losses? - StockTitan
Spotlight On February 2025's Promising Penny Stocks - Simply Wall St
4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday - Defense World
4D Molecular Therapeutics, Inc. (FDMT) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Brokerages Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $32.13 - Defense World
4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
4D Molecular's March Investor Showcase: What These Two Major Conference Appearances Signal - StockTitan
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha
4D Molecular Therapeutics' SWOT analysis: gene therapy firm's stock faces durability test - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan Capital - MarketBeat
Peapod Lane Capital LLC Purchases New Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Jefferies cuts 4D Molecular Therapeutics target to $40 - MSN
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
FDMT stock touches 52-week low at $4.42 amid sharp annual decline - Investing.com India
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $30.00 at Chardan Capital - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire
Gene Therapy In CNS Disorder Treatment Market Size Report 2032 | - openPR
Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating - Marketscreener.com
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at HC Wainwright - Defense World
BMO Capital Markets Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Market perform from an Outperform - Knox Daily
Jefferies cuts 4D Molecular Therapeutics target to $40 By Investing.com - Investing.com South Africa
4D’s new data in wet AMD bolster its phase III study vision - BioWorld Online
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Buy” Rating from HC Wainwright - Armenian Reporter
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):